CD47 Specific Neutra™ Antibody Products
Product listCD47 (Cluster of Differentiation 47), also known as integrin-associated protein IAP or OA3, is a multi-puss membrane protein overexpressed in normal tissues such as nasal epithelium and platelet and in tumors, especially epithelial tumors. CD47 binds the ligands thrombospondin THBS1 and SIRPA (SIRPα). As a modulator of integrin signaling, the adhesive CD47 may play an important role in cell-to-cell interactions, signal transduction, inflammation, apoptosis, and immunoregulation.
Its Gene ID: 961, UniProtKB ID: Q08722, and OMIM ID: 601028.
CD47-SIRPα Pathway
Increasing data suggest that CD47 plays an important role in tumor phagocytosis. The interaction between CD47 and SIRPα could cause serious signal transduction and eventually prevent phagocytosis or cytotoxicity effects of immune cells against tumor cells.
Fig.1 Therapeutic effect of CD47-SIRPα Pathway.1
Antibodies in CD47-SIRPα Therapeutics
When antibodies block the CD47-SIRPα axis, macrophages may restore their phagocytic function and exert antitumor effects. Therefore, various novel monoclonal and bispecific antibodies have been designed to improve the efficacy of cancer immunotherapy by CD7-SIRPα targeting.
- Block the CD47-SIRPα pathway with anti-CD47 monoclonal antibodies
Therapeutic blockage of the CD47-SIRPα pathway has multifold anti-tumor functions. Anti-CD47 monoclonal antibodies could stimulate tumor cell apoptosis and enhance anti-tumor immune response through four pathways including phagocytosis, ADCP/ADCC, antigen presentation, and apoptosis.
Fig.2 Therapeutic effects of anti-CD47 monoclonal antibodies.1
- Enhance cancer-specific targeting with CD47-based bispecific antibodies
Various bispecific antibodies are developed to target both CD47 and tumor-associated antigen (TAA). CD47-based bispecific antibodies are shown in Figure 3, some of which are under preclinical or clinical investigations. The CD47-based bispecific antibodies could target tumors with high precision with low “off-target” toxicity. At the same time, the CD47-based bispecific antibodies induce potent Antibody (Ab)-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity through Fc-FcR interaction.
Fig.3 Mechanisms of CD47-based bispecific antibodies.2
Creative Biolabs offers nearly ninety different anti-CD47 antibody products. These antibodies are recombinantly expressed and could be used in eleven applications. Customization of CD47-based bispecific antibodies is also available for you here.
References
- Chen, Can.; et al. "Targeting CD47 as a novel immunotherapy for breast cancer." Frontiers in Oncology 12 (2022): 924740.
- Ye, Zi-Han.; et al. "Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives." Acta Pharmaceutica Sinica B (2022).
